10x Genomics Reports Mixed Results in Q3 2024: A Dive into Financial Performance
10x Genomics, Inc., a leading player in life sciences technology, has released its financial results for the third quarter of 2024. The company, known for its innovative solutions to interrogate and understand biology, experienced a slight dip in revenue amidst notable changes in its operating expenses and product performance.
1. Revenue Breakdown: A Mixed Bag
For the three months ending September 30, 2024, 10x Genomics reported a revenue of $151.7 million, reflecting a 1% decrease from the same period last year, where revenue stood at $153.6 million. A significant highlight was the stark contrast between instruments and consumables revenue.
- Instruments Revenue: A sharp decline of 45% to $19.1 million.
- Consumables Revenue: An increase of 10% to $126.2 million.
In the nine-month period ending September 30, 2024, total revenue increased by 3% to $445.8 million. This growth was again driven primarily by consumables, which rose by 6% to $359.9 million, while instruments revenue decreased by 20% to $68.4 million.
| Nov 2023 | Oct 2024 | |
|---|---|---|
Net Income | -223.3M | -182.5M |
Profit | -223.3M | -182.5M |
Net Income Continuing | -223.3M | -182.5M |
Income Tax Expense | 4.78M | 6.63M |
Pretax Income | -218.5M | -175.9M |
Non-operating Income | 14.66M | 23.99M |
Operating Income | -233.2M | -199.9M |
Revenue | 590.9M | 629.7M |
Costs and Expenses | 824.2M | 829.6M |
Cost of Revenue | 178.0M | 210.4M |
Operating Expenses | 646.1M | 619.2M |
Research & Development | 268.6M | 262.9M |
Selling, General & Administrative | 336.0M | 336.6M |
Other Operating Expenses | 41.40M | 19.57M |
2. Operating Expenses: Control in Focus
Despite the revenue decline, 10x Genomics managed to reduce its operating expenses, which is a positive sign for investors.
Research and Development Expenses
The company's R&D expenses saw a slight decrease of 1% to $66.2 million in Q3 2024, attributed mainly to a reduction in personnel costs and allocated expenditures for facilities and IT. Over nine months, R&D expenses dropped by 4% to $197.7 million.
Selling, General, and Administrative Expenses
Similarly, selling, general, and administrative (SG&A) expenses also fell by 1% to $81.7 million for the third quarter, reflecting prudent cost management. For the nine-month period, SG&A expenses decreased by 3% to $250.5 million.
3. Income Analysis: A Move Towards Profitability?
Despite the revenue decrease, 10x Genomics reported a net income of -$35.75 million for Q3 2024, which is an improvement compared to -$92.98 million in Q3 2023. This indicates a narrowing of losses, showcasing the company's efforts to control costs and improve operational efficiency.
Income Statement Overview
- Operating Income: -$41.48 million for Q3 2024, compared to -$94.79 million in Q3 2023.
- Total Non-Operating Income: Increased significantly to $7.04 million, up from $3.05 million in the prior year.
| Nov 2023 | Oct 2024 | |
|---|---|---|
Total Assets | 948.5M | 937.7M |
Total Current Assets | 562.3M | 593.8M |
Cash and Equivalents | 311.2M | 398.1M |
Short-term Investments | 45.64M | 0 |
Net Inventories | 80.91M | 94.05M |
Accounts Receivable | 103.8M | 83.52M |
Restricted Cash and Investments | 500K | 0 |
Prepaid Expenses | 20.17M | 18.15M |
Total Non-current Assets | 386.1M | 343.9M |
Intangible Assets | 26.34M | 20.66M |
Net PP&E | 285.0M | 258.7M |
Lease Assets | 69.19M | 59.57M |
Other Non-current Assets | 5.64M | 4.90M |
Total Liabilities and Equity | 948.5M | 937.7M |
Total Liabilities | 203.3M | 214.9M |
Total Current Liabilities | 104.7M | 121.2M |
Accounts Payable and Accrued Liabilities | 47.31M | 56.29M |
Current Debt | 10.00M | 9.41M |
Current Deferred Revenue | 11.14M | 17.76M |
Other Current Liabilities | 36.25M | 37.77M |
Total Non-current Liabilities | 98.60M | 93.75M |
Non-current Deferred Revenue | 0 | 12.34M |
Other Non-current Liabilities | 98.60M | 81.40M |
Total Equity and Non-controlling Interests | 745.2M | 722.8M |
Total Equity | 745.2M | 722.8M |
4. Liquidity and Financial Position
As of September 30, 2024, 10x Genomics held $398.2 million in cash and cash equivalents, providing a solid liquidity position amid ongoing operational losses. However, the company continues to face an accumulated deficit of $1.4 billion, raising questions about future funding requirements to sustain operations and growth.
Cash Flow Insights
The net change in cash for Q3 2024 was an increase of $18.33 million, a positive turnaround from a decrease of $16.11 million in Q3 2023. This improvement was driven by a net cash inflow from operating activities of $21.64 million.
| Nov 2023 | Oct 2024 | |
|---|---|---|
Net Change in Cash | 73.18M | 83.42M |
Effect of Exchange Rate Changes | 141K | 182K |
Net Cash from Operating Activities | -27.23M | 39.17M |
Operating Profit | -223.3M | -182.5M |
Adjustment to Operating Profit | 196.1M | 221.7M |
Net Cash from Investing Activities | 87.22M | 32.05M |
Business & Interest in Affiliates | 2.5M | 0 |
Investments | -175.5M | -46.18M |
Productive Assets | 85.80M | 14.12M |
Net Cash from Financing Activities | 13.05M | 12.01M |
Equity Issuance/Repurchase | 18.87M | 12.01M |
Other Financing Activities | -5.81M | 0 |
5. Strategic Developments and Future Outlook
In recent months, 10x Genomics has focused on enhancing its product offerings. Notable introductions include the Chromium Xo, a low-cost instrument aimed at broadening access to high-performance single-cell research, suggesting a strategic pivot to capture a wider market share.
The company continues to explore acquisition opportunities and investments in technologies that would complement its existing portfolio, indicating a forward-looking strategy to innovate and expand its market presence.
Conclusion: A Path Forward
While 10x Genomics faced challenges in Q3 2024, the reduction in operating losses and strategic product launches suggest a company poised for recovery. Investors and stakeholders will be keenly watching how the company navigates the complexities of the life sciences market in the coming quarters. The focus on cost management and product innovation may ultimately position 10x Genomics favorably for future growth, despite the current operational hurdles.
